JinCore has signed a joint research agreement with a global pharmaceutical company to develop in vivo gene therapies.
The purpose of this agreement is to develop in vivo gene therapies for specific diseases using JinCore's ultra-small gene editing technology platform, 'TaRGET (Tiny nuclease, augment RNA-based Genome Editing Technology)'. TaRGET is an ultra-small gene editing technology useful for developing in vivo gene therapies, with a gene editing enzyme size smaller than CRISPR-Cas9, allowing delivery via AAV.
Under this agreement, JinCore will receive upfront payments and research funding to conduct joint research. Additionally, upon successful commercialization, JinCore will receive up to $350 million through option exercises and milestones, as well as royalties on sales. However, the partner company and target diseases involved in the agreement will remain confidential by mutual consent of both parties.
JinCore founder and CEO Yong-Sam Kim stated, “This collaboration is an opportunity to recognize the potential strengths of the TaRGET platform and to validate its usefulness as an in vivo gene therapy.”
JinCore has successfully raised a total investment of 20.7 billion KRW to date. Through this technology transfer agreement, JinCore expects to lay the foundation for entering the global market of gene therapies based on ultra-small gene editing technology.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
